patients in centres for rare diseases (ZSE-DUO): a prospective, controlled trial with a two-phase cohort design. eClinicalMedicine Vol. 65. DOI: 10.1016/j.eclinm.2023.102260 Krüger K, Lapstich AM, Reber KC, Sehlen [...] Stahmeyer JT, Krauth C (2023). Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle in [...] Krauth C (2021). How is and how should healthcare for people with multiple sclerosis in Germany be designed?-The rationale and protocol for the mixed-methods study Multiple Sclerosis-Patient-Oriented Care in
L. L., Nolte, O., Sträter, N., Alber, G. & Hoffmann, R. ( 2012 ). Api88 is a novel antibacterial designer peptide to treat systemic infections with multidrug-resistant gram-negative pathogens. ACS Chem [...] [1] Knappe, D., Zahn, M. , Sauer, U., Schiffer, G., Sträter, N. & Hoffmann, R. ( 2011 ). Rational design of oncocin derivatives with superior protease stabilities and antibacterial activities based on the
Participants in the 5th Cochrane Rehabilitation Methodological Meeting (incl. Gutenbrunner C). Designing studies and reviews to produce informative, trustworthy evidence about complex interventions in [...] Methodological Meeting Participants (incl. Gutenbrunner C). The role of single case experimental designs in evidence creation in rehabilitation. Eur J Phys Rehabil Med 2024; DOI: https://doi.org/10.237
Reaktogenität und Immunogenität von CVnCoV bei verschiedenen Dosierungen mithilfe eines adaptiven Dosisfindungsdesigns systematisch untersucht. Dies ermöglicht eine Dosissteigerung unter Verwendung vordefinierter
found their way into clinical application. In contrast to these effector CAR T cells, which are designed to kill tumour cells, we primarily deal with mechanisms of immune tolerance. In particular, regulatory
Krankheiten, prä-klinischer Sicherheit, Wirksamkeitsmodellen (inkl. Monitoring und Imaging) sowie dem Design und der Anwendung einer passenden Zell- und/ oder Vektorproduktion (inkl. Genom Editierung). Erfolgreiche
Trials with an Adaptive Design.” Biometrical Journal 48(4):574–85. Koch, Armin . 2005. “Discussion on ‘establishing Efficacy of a New Experimental Treatment in the “gold Standard” Design.’” Biometrical Journal [...] 2017. “Critical Appraisal of Arguments for the Delayed-Start Design Proposed as Alternative to the Parallel-Group Randomized Clinical Trial Design in the Field of Rare Disease.” Orphanet Journal of Rare Diseases [...] of Clinical Study Design”, RAPS Convergence, hybrid meeting – Long Beach (USA), Full Schedule 09/2023: "Estimand framework (regulatory perspective)" in Session "Innovative trial designs and estimands", CDDF
focus will be on how glycans can influence the efficiency of bone-marrow transplantation, and in the design of glycan-based strategies to improve this clinical procedure. Natalie Weber (Dr. med, PhD) Jahrgang
rodents 10:00-10:05 Break 10:05-11:05 3R-concept and applications 11:05-11:15 Break 11:15-12:30 Design and planning of animal experiments 12:30-12:45 Introduction to Q-Exam (exam preparation) Subject
isoforms complexed with the inhibitor AR-R17477 suggest a rational basis for specificity and inhibitor design. (2004) PNAS 101 , 5892-5897. Kottke T, Dick B, Fedorov R, Schlichting I, Deutzmannm R, Hegemann [...] provides new insights into RNA binding of the L1 protein family. (2000) Structure with Folding & Design 8 (4), 363-371. Fedorov R, Nevskaya N, Khairullina A, Tishchenko S, Mikhailov A, Garber M and Nikonov